Bifidobacterium infantis 35624

Strain-specific probiotic with placebo-controlled RCT signal for IBS symptoms at one tested dose, mainly in women.

Evidence
Preliminary evidenceGRADE certainty: Low
Typical dose
1 × 10⁸ CFU/day, continuous use for at least 4 weeks before assessing benefit
Time to effect
Trials assessed symptoms over 4 weeks of continuous use
Safety
Has documented cautions

Evidence ratings summarise published research on Bifidobacterium infantis 35624 in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.

Ask about Bifidobacterium infantis 35624

Interactions

Taking any medication?

Check Bifidobacterium infantis 35624 against it.

Why

Bifidobacterium infantis 35624 is a bacterial probiotic with placebo-controlled RCT evidence in irritable bowel syndrome. In the Whorwell 2006 RCT of 362 women, only the 10⁸ CFU/day dose beat placebo for abdominal pain and composite symptoms over 4 weeks; two other doses did not. A smaller 8-week trial (n=77) also found greater symptom reduction than placebo. Both trials were short.

How it works

Modulates intestinal cytokine balance, restores the IL-10:IL-12 ratio that is reduced in IBS. Surface exopolysaccharides inhibit pathogen adhesion. Bile-acid metabolism modulation may underlie part of the bowel-function effect.

Expected onset · Trials assessed symptoms over 4 weeks of continuous use

How to take

Dosage

1 × 10⁸ CFU/day, continuous use for at least 4 weeks before assessing benefit.

Timing

Once daily, with or without food

On the label

Specifically B. infantis 35624 (also marketed as B. longum subsp. infantis 35624). Generic 'Bifidobacterium' products are not equivalent.

Studied in

Adults with IBS, particularly women, seeking a strain-specific probiotic with RCT evidence; benefit in men and in every IBS subtype has not been shown.

Safety

Few side effects were reported in the trials. Avoid in critically ill or immunocompromised patients (general probiotic precaution). Interaction data are limited.
Loading interactions…

Evidence

At a glance

Whorwell 2006 Am J Gastroenterol RCT (n=362): in women with IBS, only the 1x10^8 cfu dose of B. infantis 35624 beat placebo for abdominal pain and composite symptom score over 4 weeks; two other doses did not. O'Mahony 2005 Gastroenterology RCT (n=77) also found greater symptom reduction than placebo over 8 weeks. Both trials were short.

GRADE certainty: Low — rated by Healicus using the GRADE method

Questions people ask

Does Bifidobacterium infantis 35624 work?

Whorwell 2006 Am J Gastroenterol RCT (n=362): in women with IBS, only the 1x10^8 cfu dose of B. infantis 35624 beat placebo for abdominal pain and composite symptom score over 4 weeks; two other doses did not. O'Mahony 2005 Gastroenterology RCT (n=77) also found greater symptom reduction than placebo over 8 weeks. Both trials were short. Certainty of the evidence: Low, rated by Healicus using the GRADE method.

How is Bifidobacterium infantis 35624 taken?

1 × 10⁸ CFU/day, continuous use for at least 4 weeks before assessing benefit. Timing: Once daily, with or without food. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.

Are there interactions or cautions?

Few side effects were reported in the trials. Avoid in critically ill or immunocompromised patients (general probiotic precaution). Interaction data are limited. Documented drug and supplement interactions can be looked up in the free interaction reference.

What is the evidence based on?

Sources: Whorwell et al., Am J Gastroenterol 2006, efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with IBS (RCT, n=362); O'Mahony et al., Gastroenterology 2005, Lactobacillus and Bifidobacterium in IBS: symptom responses and relationship to cytokine profiles.

One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.